BIO-TECHNE Corp

Company facts

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

Minneapolis, Minnesota

Most recent report

10-Q, filed Nov 6, 2026

Incorporated

Minnesota

Filings on record

1,001+ filings

On EDGAR

CIK 842023

Fiscal year ends

June

Filer status

Large accelerated filer

What to read: Sep 2026 10-Q

SECSift found 3 of 13 sections worth reading, with 1 positive, 3 notable, and 4 negative flags.

• Financial Statements (Item 1)

  Pending acquisition by Merck KGaA, plus a mandatory Wilson Wolf buyout for ~$1B.
  Notable

  • Shareholders approved merger with Merck KGaA on Sep 23, 2026; close expected late 2026 or early 2027.
  Negative

  • Must buy remaining Wilson Wolf equity by Dec 2027 for ~$1B if $226M revenue or $136M EBITDA milestone is met.

• Management's Discussion (Item 2)

  Pending Merck merger, $1B Wilson Wolf obligation, and segment margin divergence.
  Positive

  • Operating cash flow surged to $73.1M in Q1 FY2027 from $27.6M a year ago, a 165% increase.
  Notable

  • Pending merger with Merck KGaA; shareholder vote passed Sept 23, 2026, close expected late 2026/early 2027.
  Negative

  • Diagnostics & Spatial Biology operating margin fell from 11.2% to 7.4% in Q1 FY2027, a sharp drop.
  • Mandatory ~$1B purchase of remaining 80.1% of Wilson Wolf by Dec 31, 2027, plus contingent consideration.

• Unregistered Sales and Repurchases (Item 2)

  New $505M buyback authorized, but Merger Agreement blocks all repurchases without Parent consent.
  Notable

  • New $505M buyback authorized April 30, 2025, replacing the $400M plan from Feb 2022.
  Negative

  • Merger Agreement blocks all share repurchases without Parent's prior written consent, freezing $363.3M authorization.

What changed: Sep 2026 vs. Mar 2026

About 14% of TECH's Sep 2026 10-Q is new information. 29 paragraphs were added, 115 changed, and 44 removed. Below are the most important lines SECSift identified.

• Item 1 57
• Item 2 43
• Item 3 2
• Item 4 2
• Item 1A 1
• Item 5 1